Today, the President & CEO of Idera (NASDAQ: IDRA), Vincent Milano, bought shares of IDRA for $55.1K.
Following this transaction Vincent Milano’s holding in the company was increased by 32.45% to a total of $235.1K. In addition to Vincent Milano, 3 other IDRA executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Idera has an average volume of 1.1M.
Starting in January 2017, IDRA received 13 Buy ratings in a row. Six different firms, including Cowen & Co. and JMP Securities, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $4.24M worth of IDRA shares and purchased $110.9K worth of IDRA shares. The insider sentiment on Idera has been negative according to 16 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.
Read More on IDRA:
